ERS Genomics and NUVISAN ICB Sign CRISPR/Cas9 License Agreement
Posted on 388 ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and NUVISAN Innovation Campus Berlin (ICB) GmbH, a fully integrated contract research service provider for drug discovery and early development programs, today announced a non-exclusive license agreement granting NUVISAN ICB access to ERS Genomics’ CRISPR/Cas9 patent portfolio. NUVISAN ICB originated from a spin-out of the major pharma R&D functions of BAYER, wh...
Source: financialbuzz.com